ES2693050T3 - Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro - Google Patents

Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro Download PDF

Info

Publication number
ES2693050T3
ES2693050T3 ES09004579.0T ES09004579T ES2693050T3 ES 2693050 T3 ES2693050 T3 ES 2693050T3 ES 09004579 T ES09004579 T ES 09004579T ES 2693050 T3 ES2693050 T3 ES 2693050T3
Authority
ES
Spain
Prior art keywords
hepcidin
iron
polypeptide
mice
usf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09004579.0T
Other languages
English (en)
Spanish (es)
Inventor
Gaël Nicolas
Sophie Vaulont
Axel Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27224392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2693050(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2693050T3 publication Critical patent/ES2693050T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
ES09004579.0T 2001-05-25 2002-05-24 Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro Expired - Lifetime ES2693050T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP01401377 2001-05-25
EP01401377 2001-05-25
EP01401537 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795 2002-03-29
EP02290795 2002-03-29

Publications (1)

Publication Number Publication Date
ES2693050T3 true ES2693050T3 (es) 2018-12-07

Family

ID=27224392

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09004579.0T Expired - Lifetime ES2693050T3 (es) 2001-05-25 2002-05-24 Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro
ES02754742.1T Expired - Lifetime ES2326469T5 (es) 2001-05-25 2002-05-24 Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02754742.1T Expired - Lifetime ES2326469T5 (es) 2001-05-25 2002-05-24 Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro

Country Status (12)

Country Link
US (4) US7169758B2 (enExample)
EP (2) EP1392345B2 (enExample)
JP (4) JP4944360B2 (enExample)
CN (2) CN1612746B (enExample)
AT (1) ATE427114T1 (enExample)
AU (1) AU2002321105A1 (enExample)
CA (1) CA2448382C (enExample)
CY (1) CY1120241T1 (enExample)
DE (1) DE60231804D1 (enExample)
ES (2) ES2693050T3 (enExample)
TR (1) TR201806761T4 (enExample)
WO (1) WO2002098444A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
EP2371957A1 (en) * 2006-04-12 2011-10-05 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
AU2007275638B2 (en) * 2006-07-21 2014-01-16 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
JPWO2008047485A1 (ja) * 2006-10-17 2010-02-18 直久 友杉 活性型ヘプシジンを指標とした、鉄代謝異常の診断方法
PE20090722A1 (es) * 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8895002B2 (en) 2007-04-09 2014-11-25 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
JPWO2008146903A1 (ja) * 2007-05-31 2010-08-19 直久 友杉 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
EP2201382A4 (en) 2007-10-26 2011-01-26 Univ Utah Res Found IDENTIFICATION OF THE HEPCIDIN BINDING PLACE OF FERROPORTIN
AR069062A1 (es) * 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
EP2816059A1 (en) 2008-05-01 2014-12-24 Amgen, Inc Anti-hepcidin antibodies and methods of use
ES2432018T3 (es) * 2008-08-06 2013-11-29 Eli Lilly And Company Anticuerpos selectivos anti-hepcidina-25 y usos de los mismos
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
EP2349332B1 (en) * 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
TW201113274A (en) 2009-09-07 2011-04-16 Vifor Int Ag Novel ethanediamine hepcidine antagonists
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
US9228188B2 (en) 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
WO2013002354A1 (ja) * 2011-06-29 2013-01-03 株式会社ダナフォーム 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
EP3203991A4 (en) * 2014-10-10 2018-06-20 The Board of Regents of The University of Texas System Hif-2 inhibitors for treating iron overload disorders
KR20180109917A (ko) * 2016-01-08 2018-10-08 라 졸라 파마슈티칼 컴파니 헵시딘의 투여 방법
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
WO2019165252A1 (en) * 2018-02-23 2019-08-29 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000056879A1 (en) * 1999-03-22 2000-09-28 Universität Zürich TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS
CA2448382C (en) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP1578254B1 (en) † 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
PT2061313E (pt) * 2006-09-16 2013-09-23 Soy Labs Llc Produtos e métodos que usam péptidos de soja para reduzir os níveis de colesterol total e de colesterol ldl
PE20090722A1 (es) † 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ATE553778T1 (de) † 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
CN102245626A (zh) † 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
CA2855122A1 (en) 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
WO2015157283A1 (en) 2014-04-07 2015-10-15 Merganser Biotech Llc Hepdicin mimetic peptides and uses thereof
CA2953721A1 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof

Also Published As

Publication number Publication date
CA2448382C (en) 2013-02-19
JP2004536077A (ja) 2004-12-02
AU2002321105A1 (en) 2002-12-16
US20170340710A1 (en) 2017-11-30
JP5717319B2 (ja) 2015-05-13
ES2326469T3 (es) 2009-10-13
JP2009143938A (ja) 2009-07-02
US20160166649A1 (en) 2016-06-16
CN101884780B (zh) 2018-09-21
EP1392345B2 (en) 2018-02-28
TR201806761T4 (en) 2018-06-21
EP2186524B1 (en) 2018-02-21
ES2326469T5 (es) 2018-05-28
JP2014210775A (ja) 2014-11-13
JP5847231B2 (ja) 2016-01-20
EP1392345A2 (en) 2004-03-03
US7169758B2 (en) 2007-01-30
CN1612746B (zh) 2010-09-22
JP4944360B2 (ja) 2012-05-30
US9782453B2 (en) 2017-10-10
US20050037971A1 (en) 2005-02-17
EP2186524A1 (en) 2010-05-19
WO2002098444A2 (en) 2002-12-12
ATE427114T1 (de) 2009-04-15
JP2012111755A (ja) 2012-06-14
CN1612746A (zh) 2005-05-04
CY1120241T1 (el) 2019-07-10
EP1392345B1 (en) 2009-04-01
CA2448382A1 (en) 2002-12-12
DE60231804D1 (de) 2009-05-14
WO2002098444A3 (en) 2003-05-01
US10004784B2 (en) 2018-06-26
US9234903B2 (en) 2016-01-12
US20070124825A1 (en) 2007-05-31
CN101884780A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
ES2693050T3 (es) Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro
Jiang et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1
Jarolim et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl−/HCO3− exchanger
McInnes et al. An unusual splicing mutation in the HEXB gene is associated with dramatically different phenotypes in patients from different racial backgrounds.
EP1262187A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
DE DK et al. DE LA RECHERCHE MEDICALE (INSERM)
US20060156423A1 (en) Method of screening antiobesity agents and animal model of obesity
US20240024513A1 (en) Nucleic acids encoding human fus protein and use in the treatment of amyotrophic lateral sclerosis (als)
JP2002306021A (ja) トランスジェニックマウス及び抗肥満薬スクリーニング方法
US20070101445A1 (en) Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
Toivola Keratin 20 helps maintain intermediate filament organization in digestive epithelia
Preston Ferrer Functional analysis of the potassium channel beta subunit KCNE3
Ferrer Functional analysis of the potassium channel beta subunit KCNE3
WO2002097079A2 (en) Gene encoding molecular motor protein and diagnosis method for the disease related to the gene